Member Info for CauldStream7

Nolupus:

Is this a denial of Nolupus=nobbygnome? Your reply seems very gnomic, and very typical of your posts.

....Infant Drug Status which will accelerate the trial process. We all know that IMM is looking for a pharma to finance the CIDP and we believe the BOD when it says it expects to find a partner for the CIDP trial this year. There have been trials/investigations by IMM which have led to the approval by FDA of the P140 trial in the case of CIDP. FDA support for the new Phase 2/3 CIDP trial is not in doubt, only the finance for it.

Flash212:

You omit to say that meetings with FDA have been held and that FDA has given its agreement for a drug from the P140 platform can be used in an adaptive Phase 2/3 Trial on patients with CIDP.

The recent RNS issued by Immupharma on 6 March also states that an application has been drawn up in collaboration with Simbec-Orion which has been appointed as CRO to take charge of the CIDP adaptive trial to apply for CIDP for Infant Drug

Dallo:

And if is bought by a large pharma, what valuation are we looking at? Amolyt cost AZN $1.05 billion. Can you imagine a valuation much greater than that for the P140 platform of peptides, £5 billion perhaps?

Nolupus:

Thanks for your comment.

I know that it is the responsibility of the CRO, Simbec - Orion, to post information about the timetable and other details of the Lupuzor trial on the clinical trials website, but surely they keep IMM and Avion up to date on their progress. They should pass on this information to private investors like us at regular intervals.

Dallo:

Your last post was an important reminder of the correct situation in regard to the Phase 3 Lupuzor trial. Thanks.

Now, it would be helpful if we could be advised of the timings of the Phase 3 programme: when the patient recruitment will be completed; the likely spacing of the intermediate reports on the dosing regimes and similar information of the Phase 2/3 CIDP trial. It's also been a considerable time since we have had any hard news on BioAMB's progress towards commercialisation.

Dallo:

Well, it's beyond my comprehension, too.

You say the French are better at raising finance for their small research pharmas. But IMM has good French links - its labs are in Bordeaux, I believe, and the whole purpose of IMM is to commercialise the research by France's leading scientific organisation into peptides, etc. So why on earth does it not carry the sort of market valuation which Amolyt has?

Dallo: You are a far more experienced stock market investor than I am. Do you have any insight into why the recently acquired small pharma called Amolyt which has one peptide drug in a Phase 3 trial, has been valued by AZN at $800 million up front plus a further $205 million dependent on achieving sales targets? At the same time IMM, with more peptide drugs on its P140 platform at |Phase 3 stage than Amolyt, is presently valued at £8 million and estimated by you to be worth £50 million. Why the enormous disparity in the value of these two small pharmas? I don't get it.

Dallo; I am following the same buying policy as you. I reckon any price below 2p is a real bargain.

Dallo:

Perhaps the news of acquisition by AZN of Amolyt, a small French pharma company which specialises in a peptide drug treatment of a rare disease may be filtering through to large pharmas also looking to strengthening their position in the treatment of autoimmune diseases. Bring on Immupharma. Doesn't it fit the bill?

And consider the price that AZN is prepared to spend to acquire Amolyt - $ 1.05 billion. Wow!

Alexander: As I have said before, you can't reason with Flash. You and I believe in the integrity of the IMM Board and are waiting and expecting announcements of new commercial partnerships which will finance IMM's research in the future.

Flash on the other hand has one objective: to depress the SP of IMM for as long as possible by dripping poisonous predictions of the SP falling below 1p. That is his only goal, at least on this bulletin board. But of facts he has none.

Pokerchips;

No one said that financing for a small pharma comes cheaply, so yes, and extra £2m in exchange for 100 million shares is a high price to pay. This is about survival with the goal being multi million bucks when the phase 3 trials are successful and deals are struck with other pharmas for the development for the drugs in the IMM pipeline.

That is why I still buy shares because the share price is below the 2p level which not so long ago was seen as unbelievably cheap. Hopefully we will soon see these ultra low prices recede into the past and the price will head back into double figures.

Dallo:

You are wasting your time trying to reason with dedicated naysayers like Lambo and Mystic Mike. I listened to Tim giving his Proactive interview today and found what he had to say persuasive.

I am somewhat glad that these naysayers exist - they help to depress the share price and allow me to continue to buy IMM shares at bargain basement prices - excellent news for me and my limited budget.

So carry on Mystic Mike and snivel away!

Wildbunch:

Wouldn't that be luvverly!

Thanks Dallo. Lisa's response to you is consistent with her response to me a week or two ago. Like you, I believe that she is honest in her belief that IMM has got a great future but it takes longer to achieve deals with prospective partners than investors (including herself?) had imagined.

Dallo:

Maybe she is working on a new RNS.

.....better.

ab: Thanks for your upbeat reflections. As good as a positive RNS.

Dallo

I'm sure that Lisa is only too well aware of the importance of issuing a RNS as soon as there is some news to report. But if there ain't any deal to report, there is not much she can do.

Only in the case of the Phase 3 Lupuzor trial is the company in more or less control of events and they must be surely trying to put a rocket under Simbec-Orion to get a move on with finalising patient recruitment and announcing a timetable for the Trial.

Wildtiger:

No, I have not sold and don't intend to throw in the towel at this stage.

Pig-headed? Stupid? Time will tell.

Adastra.

In your contribution of 24 January you commented " End February is time enough for things to fall into place."

And in your last contribution, on 7 February, you said "Having done lengthy background research I expect this to be a highly rewarding share."

Don't you think with the avalanche of share sells this morning that you were a little too optimistic about IMM having until end of February to pull off a significant collaboration on one of its pipeline drugs and/or announced a starting date for patient testing under the Ph3 Lupuzor trial? Such an announcement might have restored belief in the market enough to defeat the selling pressure.

What is the source of these clusters of sell orders?